Company Overview and News

 
38 Basic Materials 'Safer' Dividends For March

2018-03-28 seekingalpha
38 of 77 Basic Materials top yield stocks were tagged "safer" for dividends because they showed positive annual-returns, and free cash-flow yields greater than their dividend yields 3/23/18.

 
Mercer, Schweitzer And Westlake Top 'Safer' Dividend Basic Materials February Gains

2018-02-21 seekingalpha
Top-gain ten "Safer" dividend Basic Materials stocks per analyst 1yr. targets, HUIHY; SHLTF; CELTF; LYB; AHGP; CPAC; ICL; WLKP, SWM, & MERC averaged 12.99% February net.

 
SunCoke, Schweitzer And Westlake Pace 'Safer' Dividend Basic Materials Gains For January

2018-01-21 seekingalpha
Top-gain ten "Safer" dividend Basic Materials stocks per analyst 1yr. targets, SOUHY; RTNTF; ERELY; ICL; VEDL; HUIHY; AHGP; WLKP, SWM, & SXCP averaged 7.7% January gains.

 
Coal & Chemicals Pace 'Safer' Dividend Basic Materials Gains In December

2017-12-16 seekingalpha
Top-gain ten Basic Materials "Safer" dividend stocks per analyst 1yr. targets - AHGP; ICL; RIO; WLKP; FELP; IPHS; NRP; SXCP, ARLP, & CCR - averaged 23.7% gains.

 
My First Big Mistake - The Case Of Huabao International Holdings

2017-10-13 valuewalk
I started investing when I was not even allowed to drive yet, but my investing activities became more serious in 2012, after I had relocated to Hong Kong, started to work and had some money to actually invest. It didn’t take much time for the inexperienced me to make his first important mistake. At the time, I was already a big fan of value investing and knew the main concepts quite well. However, I was lacking in experience and investing is an industry where a few grey hair can help (which is now starting to happen…).

 
My First Big Mistake - The Case Of Huabao International Holdings

2017-09-13 valuewalk
I started investing when I was not even allowed to drive yet, but my investing activities became more serious in 2012, after I had relocated to Hong Kong, started to work and had some money to actually invest. It didn’t take much time for the inexperienced me to make his first important mistake. At the time, I was already a big fan of value investing and knew the main concepts quite well. However, I was lacking in experience and investing is an industry where a few grey hair can help (which is now starting to happen…).

 
$31.41 Billion Flavors and Fragrances Market - Forecasts From 2016 to 2021: Focus Towards a Healthier Lifestyle and Increasing Application of Flavors and Fragrances - Research and Markets

2017-02-24 prnewswire
Research and Markets has announced the addition of the "Flavors and Fragrances Market - Forecasts from 2016 to 2021" report to their offering.

 
Hong Kong stocks retreat as developers, energy explorers decline

2016-11-24 themalaymailonline
Hong Kong’s benchmark index has fallen more than 6 per cent since its September peak, as inflows from the mainland dwindled and amid expectations the Federal Reserve will raise interest rates next month. — Reuters picHONG KONG, Nov 24 — Hong Kong stocks slipped, with the benchmark index headed for its biggest drop in more than a week, as property companies and oil firms slid.

Related Articles

SGMO: Sangamo BioSciences and Research Report

2018-05-19 - Asif

OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...

HMNY: Helios and Matheson Analytics and Research Report

2018-05-19 - Asif

Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...

BSTG: Biostage Analysis and Research Report

2018-05-17 - Asif

Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...